HomeBUSINESS
BUSINESS

Kowa Continues Heavy GP Pitch for Parmodia in July: Anterio
(Sep.13.2018)

Kowa continued to put its sales force heavily behind its hyperlipidemia drug Parmodia (pemafibrate) in July, which hit the market in June after skipping three rounds of price listing since its approval in July last year, market research firm Anterio’s “Impact Track” survey showed ...
(LOG IN FOR FULL STORY)

News Calendar